RFK Jr. Moves to Restore Access to 12 Peptides — What It Means

In recent weeks, Department of Health and Human Services Secretary Robert F. Kennedy Jr. has publicly indicated that HHS intends to move toward restoring compounding access to twelve peptides that were restricted under the FDA’s 2023 Category 2 bulk drug substance decision. The announcement has generated significant attention in the peptide therapy community. This article explains the regulatory context, which peptides are involved, what the announcement actually means procedurally, and what it does not mean.

The 2023 Category 2 Decision: What It Was

In September 2023, the FDA moved several peptides to Category 2 of its bulk drug substances list under the 503A compounding pathway. Category 2 designation means the FDA has determined that there is insufficient clinical data in the human regulatory record to support compounding the substance for routine dispensing. Among the peptides moved to Category 2 were BPC-157, CJC-1295, and several others that had developed significant clinical followings in functional medicine, sports medicine, and longevity practices.

The practical effect was that licensed compounding pharmacies could no longer compound these peptides for routine in-office dispensing through the standard 503A pathway. Access through legitimate pharmacy channels was curtailed significantly, and demand shifted — in some cases — toward the unregulated research chemical market that the FDA subsequently targeted in its March 2026 enforcement actions.

The Kennedy Announcement

Secretary Kennedy’s public statements indicate that HHS is pursuing reclassification of twelve peptides, moving them away from Category 2 restriction and toward a regulated compounding access pathway. The peptides identified in public reporting include BPC-157, TB-500, GHK-Cu, and MOTS-c, among others. The policy rationale cited by Kennedy aligns with a broader HHS emphasis on expanding access to compounds with documented clinical use and safety records, while maintaining quality standards.

What This Means for BPC-157, TB-500, GHK-Cu, and MOTS-c

If the reclassification moves forward through the formal regulatory process, these compounds would be eligible for compounding under standard 503A pathways again. Licensed compounding pharmacies could dispense them with full compliance, batch testing, and the quality infrastructure that the current gray market cannot provide. For patients who have been using these compounds, that would mean access to verified, USA-compounded material through legitimate channels rather than navigating an unregulated market.

MOTS-c deserves specific mention as a compound with growing interest in longevity research. It is a mitochondria-derived peptide with preliminary data suggesting metabolic and anti-aging effects. Its inclusion in the proposed reclassification reflects a broadening of the regulatory conversation beyond the most commercially prominent peptides.

What This Does Not Mean

As of the time of writing, no reclassification has been enacted. Public statements from a cabinet secretary are not regulatory changes. Any reclassification must move through the FDA’s formal rulemaking process, which includes public comment periods, agency review, and finalization of new rules. That process takes time — historically, months to years for significant regulatory changes.

This means the current regulatory landscape has not changed. Peptides that are currently in Category 2 remain in Category 2. Buyers should not treat a policy announcement as a green light to source from unregulated channels on the assumption that the regulatory environment is about to relax. The enforcement actions against research peptide companies remain in effect. The quality and safety arguments for sourcing from licensed USA compounding pharmacies remain unchanged regardless of future regulatory direction.

The Bigger Picture

The Kennedy announcement represents the most significant policy signal toward expanded peptide access in several years. It suggests that at the federal level, there is appetite for a regulatory pathway that distinguishes between uncontrolled overseas research peptides and quality-controlled USA-compounded peptides — which is the distinction that has always mattered from a patient safety standpoint.

Greenstone Peptides operates within the legitimate compounding pharmacy model now and will continue to operate within it under any future regulatory framework. Our interest is in quality and traceability, not in regulatory gray zones. When and if reclassification creates new compounding pathways for BPC-157, TB-500, and other currently restricted peptides, those pathways will be available through our licensed pharmacy partners with the same testing and documentation standards we apply to everything we currently offer.

The Bottom Line

RFK Jr.’s announcement is a meaningful policy signal, not an enacted change. It suggests regulatory momentum toward expanded compounding access for twelve peptides including BPC-157, TB-500, GHK-Cu, and MOTS-c. Formal reclassification requires a regulatory process that has not yet completed. Until it does, the current rules apply — and the case for sourcing from licensed USA compounding pharmacies with full quality controls remains the only defensible position regardless of where the regulatory landscape moves.

Sources

1. FDA Advisory Committee Calendar — PCAC Meeting July 2026. fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026

2. Federal Register — PCAC Meeting Notice, Apr 2026. federalregister.gov/documents/2026/04/16/2026-07361/pharmacy-compounding-advisory-committee-notice-of-meeting-establishment-of-a-public-docket-request

3. STAT News — "FDA panel will meet to discuss allowing broader access to certain peptides." statnews.com/2026/04/15/peptides-fda-panel-to-discuss-broader-access-compounding/